pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), ... versus pemetrexed plus platin, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 1.12 [0.73, 1.72]< 10%1 study (1/-)30.3 %NAnot evaluable crucial-
progression or deaths (PFS) 0.47 [0.34, 0.65]< 10%1 study (1/-)100.0 %NAnot evaluable important-
objective responses (ORR) 4.37 [2.63, 7.27]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

TRAE (grade 3-4) 0.98 [0.62, 1.54]< 10%1 study (1/-)54.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 3.93 [0.21, 74.98]< 10%1 study (1/-)18.4 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 0.74 [0.36, 1.50]< 10%1 study (1/-)80.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.